{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T21:06:48Z","timestamp":1782940008102,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00277-023-05161-1","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T16:02:46Z","timestamp":1679500966000},"page":"1011-1017","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Superiority of polatuzumab vedotin over other novel agents in previously untreated ABC-type diffuse large B-cell lymphoma: a network meta-analysis of 20 RCTs"],"prefix":"10.1007","volume":"102","author":[{"given":"Zhixin","family":"Sheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunwu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baolong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6586-377X","authenticated-orcid":false,"given":"Lida","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"issue":"6769","key":"5161_CR1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769):503\u2013511","journal-title":"Nature"},{"issue":"25","key":"5161_CR2","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346(25):1937\u20131947","journal-title":"N Engl J Med"},{"key":"5161_CR3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1182\/asheducation-2017.1.284","volume":"1","author":"A Davies","year":"2017","unstructured":"Davies A (2017) (2017) Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently? Hematol Am Soc Hematol Educ Program 1:284\u2013294","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"21","key":"5161_CR4","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1200\/JCO.18.01994","volume":"37","author":"NL Bartlett","year":"2019","unstructured":"Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD et al (2019) Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance\/CALGB 50303. J Clin Oncol 37(21):1790\u20131799","journal-title":"J Clin Oncol"},{"issue":"31","key":"5161_CR5","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","volume":"35","author":"U Vitolo","year":"2017","unstructured":"Vitolo U, Trn\u011bn\u00fd M, Belada D, Burke JM, Carella AM, Chua N et al (2017) Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol 35(31):3529\u20133537","journal-title":"J Clin Oncol"},{"issue":"6","key":"5161_CR6","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1080\/0284186X.2021.1898048","volume":"60","author":"Oren Pasvolsky","year":"2021","unstructured":"Pasvolsky Oren, Rozental Alon, Raanani Pia, Gafter-Gvili Anat, Gurion Ronit (2021) R-CHOP compared to R-CHOP + X for newly diagnosed diffuse large B-cell lymphoma: a systematic review and meta-analysis. Acta Oncol 60(6):744\u2013749","journal-title":"Acta Oncol"},{"issue":"12","key":"5161_CR7","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1007\/s00277-021-04623-8","volume":"100","author":"G Villacampa","year":"2021","unstructured":"Villacampa G, Dienstmann R, Bosch F, Abrisqueta P (2021) Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis. Ann Hematol 100(12):2969\u20132978","journal-title":"Ann Hematol"},{"issue":"4","key":"5161_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP et al (2022) Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 386(4):351\u2013363","journal-title":"N Engl J Med."},{"key":"5161_CR9","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12458724","volume":"33","author":"Sofia Dias","year":"2013","unstructured":"Dias Sofia, Sutton Alex J, Ades AE, Welton Nicky J (2013) Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 33:607\u2013617","journal-title":"Med Decis Making"},{"issue":"5","key":"5161_CR10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","volume":"20","author":"A Davies","year":"2019","unstructured":"Davies A, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U et al (2019) Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol 20(5):649\u2013662","journal-title":"Lancet Oncol"},{"issue":"15","key":"5161_CR11","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.18.02403","volume":"37","author":"A Younes","year":"2019","unstructured":"Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J et al (2019) Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center b-cell diffuse large B-cell lymphoma. J Clin Oncol 37(15):1285\u20131295","journal-title":"J Clin Oncol"},{"issue":"12","key":"5161_CR12","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1200\/JCO.20.01366","volume":"39","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W et al (2021) ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo Plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol 39(12):1317\u20131328","journal-title":"J Clin Oncol"},{"issue":"31","key":"5161_CR13","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","volume":"35","author":"JP Leonard","year":"2017","unstructured":"Leonard JP, Kolibaba KS, Reeves JA, Tulpule A, Flinn IW, Kolevska T et al (2017) Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with nongerminal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol 35(31):3538\u20133546","journal-title":"J Clin Oncol"},{"issue":"12","key":"5161_CR14","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.20.01375","volume":"39","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski GS, Hong F, Scott DW, Macon WR, King RL, Habermann TM et al (2021) Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase II US Intergroup Study ECOGACRIN E1412. J Clin Oncol. 39(12):1329\u20131338","journal-title":"J Clin Oncol."},{"issue":"16","key":"5161_CR15","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1182\/blood-2015-03-632430","volume":"126","author":"F Offner","year":"2015","unstructured":"Offner F, Samoilova O, Osmanov E, Eom HS, ToppMS Raposo J et al (2015) Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood 126(16):1893\u2013901","journal-title":"Blood"},{"issue":"9880","key":"5161_CR16","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","volume":"381","author":"D Cunningham","year":"2015","unstructured":"Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P et al (2015) Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 381(9880):1817\u201326","journal-title":"Lancet."},{"issue":"6","key":"5161_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","volume":"14","author":"Richard Delarue","year":"2013","unstructured":"Delarue Richard, Tilly Herv\u00e9, Mounier Nicolas, Petrella Tony, Salles Gilles, Thieblemont Catherine et al (2013) Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 14(6):525\u201333","journal-title":"Lancet Oncol"},{"issue":"29","key":"5161_CR18","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.19.03418","volume":"38","author":"PJ Lugtenburg","year":"2020","unstructured":"Lugtenburg PJ, de Nully Brown P, van der Holt B, D\u2019Amore FA, Koene HR, de Jongh E et al (2020) Rituximab-CHOP with early rituximab intensification for diffuse large B-cell lymphoma: a randomized phase III trial of the HOVON and the nordic lymphoma group (HOVON-84). J Clin Oncol 38(29):3377\u20133387","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05161-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05161-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05161-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T06:05:52Z","timestamp":1681365952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05161-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["5161"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05161-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,22]]},"assertion":[{"value":"26 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This pooled analysis was approved by the institutional review boards of Weifang People\u2019s Hospital, in accordance with the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}